Overactive bladder (OB), formerly known as urge incontinence, is the most common type of urinary incontinence. The appropnate management of OB is more important than ever since the number of persons with OB is expected to increase with the growing elderly population, the group at highest risk for OB. At the same time new drugs are available that are generally as effective and better tolerated than the current "gold standard" drug therapy. To facilitate the selection of optimum pharmacotherapy for OB, the important distinguishing properties of the traditional and new drug therapies for OB will be reviewed.
National Institues of Health.Urinary incontinence in adults: National Institutes of Health consensus development conference. J Am Geriatr Soc. 1990; 38:265-72.
2.
Fantl JA, Newman DK, Coiling J, et al.Urinary Incontinence in Adults: Acute and Chronic Management. Rockville, MD: U.S. Dept of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research ;.1996Clinical Practice Guidelines No. 2, 1996 Update. AHCPR publication 96-0682.
3.
Lackner TE.Pharmacologic management of urinary incontinence. Annals of Long-Term Care. 2000; 8:29-37.
4.
Wagner TH, Hu T-W.Economic costs of urinary incontinence in 1995. Urol. 1998; 51:355-61.
5.
Lagace EA, Hensen W, Hickner JM.Prevalence and severity of urinary incontinence in ambulatory adults: an UPR Net study. J Fam Pract. 1993; 36:610-4.
6.
Brubaker L, Benson JT, Bent A, et al.Transvaginal electrical stimulation for female urinary incontinence . Am J Obstet Gynecol. 1997; 177:536-40.
7.
Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, Candib D.Behavioral vs drug treatment for urge urinary incontinence in older women . JAMA. 1998; 280:1995-2000.
8.
Schnelle JF.Treatment of urinary incontinence in nursing home patients by prompted voiding. JAm Geriatr Soc. 1990; 38:356-60.
9.
Ouslander JG, Schnelle JF, Uman G, Fingold S, Nigman JG, Tuico E, Bates Jensen B.Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc. 1995; 43:610-7.
10.
Nilsson CG, Lukkari E, Haarala M, Kivela A, Hakonen T, Kiilholma P.Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. Neurourol Urodyn. 1997; 16:533-42.
11.
Birns J, Malone Lee JG, and the Oxybutynin CR Study Group. Controlled-release oxybutynin maintains efficacy with a 43% reduction in side effects compared with conventional oxybutynin treatment . Neurourol Urodyn. 1997; 16:429-30.
12.
Schmidt RA, The Oxybutynin XL Study Group. Efficacy of controlled-release, once-α-day oxybutynin chloride for urge urinary incontinence. Jerusalem: International Continence Society; Sept. 14-17, 1998:188.
13.
Anderson RU, Mobley D, Blank B, et al.Once daily controlled versus immediate-release oxybutynin chloride for urge urinary incontinence. OROS® Oxybutynin Study Group. J Urol . 1999; 161:1809-12.
14.
Katz IR, Sands LP, Bilker E, et al.Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc . 1998; 46:8-13.
15.
Amarenco G, Marquis P, McCarthy C, Richard F.Efficacy of oxybutynin on health related quality of life (HRQL) in 1701 women suffering from urinary urge incontinence (UUI. Eur Urol . 1998; 33(suppl 1):32-8.
16.
Appell RA.Clinical efficacy and safety of tolterodine in the treatment of overactive bladder : a pooled analysis. Urology. 1997; 50 (suppl 6A):90-6.
ALZA Corporation.Data on file. Palo Alto, CA; 1999.
19.
Paine MF, Khalighi M, Fisher JM, et al.Characterisation of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther . 1997; 283:1552-62.
20.
Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol. 1999; 39:289-96.
21.
Schmidt RA, The Oxybutynin XL Study Group. Efficacy of controlled-release, once-a-day oxybutynin chloride for urge urinary incontinence. Jerusalem: International Continence Society; Sept. 14-17, 1998:188.
22.
Nilsson CG, Lukkari E, Haarala M, Kivela A, Hakonen T, Kiilholma P.Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. Neurourol Urodyn. 1997; 16:533-42.
23.
Gleason DM, Susset J, White C, et al.Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology. 1999 ; 54:420-3.
24.
Birns J, Malone Lee JG, and the Oxybutynin CR Study Group. Controlled-release oxybutynin maintains efficacy with a 43% reduction in side effects compared with conventional oxybutynin treatment . Neurourol Urodyn. 1997; 16:429-30.
25.
Susset JG, Gleason DM, White CF, et al.Open-label safety and dose conversion/determination of once-daily OROS oxybutynin chloride for urge urinary incontinence (U-UI) [abstract no. 070].
26.
Zinner NR.Patient-oriented outcomes with once-daily oxybutynin for urge incontinence [abstract]. Obstet Gynecol. 1999; 93 (suppl):29.
27.
Moore KH, Hay DM, Imrie AE, Watson A, Goldstein M.Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol. 1990; 66:479-85.
28.
Riva D, Casolati E.Oxybutynin chloride in the treatment of female idiopathic bladder instability. Clin Exp Obstet Gynecol. 1984; 11:37-42.
29.
Pharmacia & Upjohn.Detrol (tolterodine) prescribing information. Kalamazoo, MI; March 1998.
Pharmacia & Upjohn.Data on file. Kalamazoo, MI; 1998.
32.
Chancellor M, Freedman S, Mitcheson HD, Antoci J, Primus G, Wein A. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest. 2000; 19:83-91.
33.
Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P.Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. 1998; 81:42-8.
34.
Millard R, Tuttle J, Moore K, Susset J, Clarke B, Dwyer P, Davis BE.Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol. 1999; 161:1551-5.
35.
Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S.Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol. 1999; 10:283-9.
36.
Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new anti-muscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder . Br J Urol. 1998; 81:801-10.
37.
Jonas U, Hofner K, Madersbacher H. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation . World J Urol. 1997; 15:144-51.
38.
Owens RG, Karram MM.Comparative tolerability of drug therapies used to treat incontinence and enuresis. Drug Safe. 1998; 2:123-39.
39.
Milner G, Hills NF.A double-blind assessment of antidepressants in the treatment of 212 enuretic patients. Med J Aust. 1968; 1:943-7.
40.
Castleden CM, George CF, Renwick AG, Asher MJ. Imipramine—A possible alternative to current therapy for urinary incontinence in the elderly. J Urol. 1981; 125:318-20.
41.
Lose G, Jorgenson L, Thuriedborg P.Doxepin in the treatment of female detrusor overactivity : a randomized double-blind crossover study. J Urol. 1989 ; 142:1024-6.
42.
Deguecker J.Drug treatment of urinary incontinence in the elderly: controlled trial with vasopressin and propantheline bromide. Geront Clinica. 1965; 7:311-7.
43.
Zorzitto ML, Jewett MAS, Fernie GR, et al.Effectiveness of propantheline bromide in the treatment of geriatric patients with detrusor instability. Neurol Urodyn. 1986; 5:133-40.
Thuroff JW, Bunke B, Ebner A, deGeeter P, Hanappel J, et al.Randomized, double blind, multicentre trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol. 1991; 145:813-7.
46.
Holmes DM, Montz FJ, Stanton SL.Oxybutynin versus propantheline in the management of detrusor instability: a patient-regulated variable dose trial. Br J Obstet Gynaecol . 1989; 96:607-12.
47.
Beck RP, Arnusch D, King C.Results in treating 210 patients with detrusor overactivity incontinence of urine . Am J Obstet Gynecol. 1976; 125:593-6.
48.
Castleden CM, Duffin HM, Millar AW.Dicyclomine hydrochloride in detrusor instability : a controlled clinical pilot study. J Clin Exp Gerontol. 1987; 9:265-70.
49.
Arikian SR, Casciano J, Doyle JJ, Tarride J-E, Casciano RN.A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Managed Care Interface2000 Feb:88-94.
